Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Congenital thrombotic thrombocytopenic purpura is the hereditary form of thrombotic thrombocytopenic purpura (TTP) characterized by profound peripheral thrombocytopenia, microangiopathic hemolytic anemia (MAHA) and single or multiple organ failure of variable severity.
Features include common findings: Jaundice; and sometimes findings: Stroke, Respiratory distress, and Transient ischemic attack. 20 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Blood and immune system | 4 | Hemolytic-uremic syndrome, Microangiopathic hemolytic anemia, Increased immature red blood cells (reticulocytosis) |
Kidneys and urinary system | 4 | Protein in the urine (proteinuria), Abnormal renal physiology, Microscopic hematuria |
Brain and nerves | 3 | Stroke, Transient ischemic attack, Tremor |
Heart and blood vessels | 3 | Stroke, Myocardial infarction, Transient ischemic attack |
Lab test results | 2 | Increased circulating lactate concentration, Elevated creatinine (kidney function marker) (elevated circulating creatinine concentration) |
Digestive system | 2 | Jaundice, Prolonged neonatal jaundice |
Lungs and breathing | 1 | Respiratory distress |
Metabolism | 1 | Fever |
Pregnancy and birth | 1 | Prolonged neonatal jaundice |
ADAMTS13 encodes ADAM metallopeptidase with thrombospondin type 1 motif 13 (1,427 aa). Cleaves the vWF multimers in plasma into smaller forms thereby controlling vWF-mediated platelet thrombus formation
Congenital thrombotic thrombocytopenic purpura is caused by mutations in the ADAMTS13 gene on chromosome 9.
The ADAMTS13 protein participates in ADAMTS13 variant pathway.
ADAMTS13 is classified as a druggable target (Cell Surface, Druggable Genome, Enzyme, Neutral Zinc Metallopeptidase, and Protease categories) with score 0.0.
99 pathogenic variants reported in ADAMTS13 in ClinVar, including hotspot variants 2708157 and 2073261.
Variant | Significance | Review Stars | Hotspot |
|---|---|---|---|
2708157 | Conflicting classifications of pathogenicity | — | Yes |
2073261 | Conflicting classifications of pathogenicity | — | Yes |
1336042 | Conflicting classifications of pathogenicity | — | Yes |
1306208 | Conflicting classifications of pathogenicity | — | Yes |
1303178 | Conflicting classifications of pathogenicity | — | Yes |
Genetic testing for ADAMTS13 is available. Testing is considered confirmatory for diagnosis.
Phenotype severity distribution: 1 common feature.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
1 clinical trial registered, 1 recruiting. Interventions under study include other interventions. Research is primarily sponsored by academic and government institutions.
42 publications have been identified in PubMed for congenital thrombotic thrombocytopenic purpura. Research spans Case Report / Case Series (26%), Review / Meta-Analysis (21%), and Basic Science / Preclinical (17%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 11 | 26% |
Research summaries | 9 | 21% |
Laboratory research | 7 | 17% |
Clinical study results | 5 | 12% |
Disease patterns and progression | 5 | 12% |
Other research | 3 | 7% |
New treatment approaches | 2 | 5% |
Robichaux TP (2026). [PMID: 41695966](https://pubmed.ncbi.nlm.nih.gov/41695966/). *Journal of the advanced practitioner in oncology*. [Gene Therapy / Novel Therapeutics]
Poznyakova J (2026). [PMID: 42196618](https://pubmed.ncbi.nlm.nih.gov/42196618/). *Int J Mol Sci*. [Basic Science / Preclinical]
Barker E (2026). [PMID: 42107974](https://pubmed.ncbi.nlm.nih.gov/42107974/). *Br J Haematol*. [Epidemiology / Natural History]
Wang A (2026). [PMID: 42158987](https://pubmed.ncbi.nlm.nih.gov/42158987/). *Blood Coagul Fibrinolysis*. [Case Report / Case Series]
Windyga J (2026). [PMID: 41035409](https://pubmed.ncbi.nlm.nih.gov/41035409/). *Haematologica*. [Review / Meta-Analysis]
Carter MA (2026). [PMID: 41692098](https://pubmed.ncbi.nlm.nih.gov/41692098/). *Journal of thrombosis and haemostasis : JTH*. [Other]
Kaur H (2026). [PMID: 42198833](https://pubmed.ncbi.nlm.nih.gov/42198833/). *Expert Rev Hematol*. [Review / Meta-Analysis]
Kumar V (2026). [PMID: 41751340](https://pubmed.ncbi.nlm.nih.gov/41751340/). *Biomedicines*. [Clinical Trial Publication]
Joly BS (2026). [PMID: 40875883](https://pubmed.ncbi.nlm.nih.gov/40875883/). *Blood advances*. [Review / Meta-Analysis]
Laemmle A (2026). [PMID: 41680850](https://pubmed.ncbi.nlm.nih.gov/41680850/). *Thrombosis journal*. [Basic Science / Preclinical]
Data assembled from 9 of 12 sources · Last updated Sep 20, 2026, 5:36 PM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
AI-curated news mentioning congenital thrombotic thrombocytopenic purpura
Updated Sep 11, 2026
A case report highlights pancreatitis and myocardial infarction as complications of thrombotic thrombocytopenic purpura (TTP). This finding underscores the need for awareness of these potential severe outcomes in TTP patients.
A recent study published in PubMed examines the natural history and treatment outcomes of congenital thrombotic thrombocytopenic purpura (cTTP). This retrospective longitudinal cohort study provides valuable insights into the disease's progression and management.
A recent study highlights the psychological health, cognition, and overall well-being impacts of hereditary thrombotic thrombocytopenic purpura (TTP) on patients. The findings underscore the need for comprehensive care approaches that address both physical and mental health aspects.